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Abstract—(S)-(1,2,3,6-Tetrahydropyridazin-3-yl)methanol was synthesized in two steps by the Diels–Alder 
reaction of penta-2,4-dien-1-ol with diethyl azodicarboxylate in the presence of (S)-BINOL as chiral catalyst. 
The subsequent Boc-protection of the 2-position of the pyridazine ring, ring-closing carbonylation of the 
hydroxy group, and deprotection afforded a bicyclic iminosugar analog. The structure of the isolated compounds 
was proved by NMR, IR, and mass spectra and elemental analyses.
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Azasugars or iminosugars are organic compounds 
containing a ring nitrogen atom that have attracted 
keen interest in recent time [1–3]. The reason is that 
shift of the nitrogen atom to the pseudoanomeric 
position (which corresponds to the anomeric position 
in a mono saccharide) in a classical nojirimycin type 
iminosugar glucosidase inhibitor sharply enhances the 
inhibitory activity; therefore, such glucosidase inhibi-
tors were discerned as a separate class, so-called 
1-azasugars [4, 5]. Among this class of compounds, 
1-azafagomine was shown to efficiently inhibit both α- 
and β-gluco sidases [6, 7]. The biological activity of 
1-azafagomine originates from the fact that it mimics 
transition states in the cleavage of α- and β-glucosides 
in the protonated form [8]. This stimulated develop-
ment of methods for the synthesis of new iminosugar 
analogs. Concurrently, in vivo assays revealed broad 
spectrum of biological activity of these compounds, in 
particular antiviral, antibacterial, antiprotozoal, anti-
parasitic, antipsoriatic, antifungal, nematicidal, insec-
ticidal, anti-inflammatory, and antitumor [10–15]. 
Glycosidase inhibitors were found to be useful in the 
treatment of lysosomal memory disorders (Gaucher, 
Fabry, Sandhoff, and Tay-Sachs diseases); they can 
also be used as antidiabetic, antimicrobial, anticancer, 
and immunosuppressive agents [8, 9]. Obviously, the 
scope of application of iminosugars has become very 
interesting for both chemical and biological studies.
Taking into account the significance of iminosugars, 
we set ourselves the goal of obtaining new bicyclic 
1-azafagomine analogs on the basis of (S)-(1,2,3,6-tet-
rahydropyridazin-3-yl)methanol (3). The starting com-
pound was penta-2,4-dien-1-ol (1) which was prepared 
from penta-2,4-dienoic acid according to [16]. 
[4+2]-Cycloaddition of 1 and diethyl azodicarboxylate 
(DEAD) in the presence of (S)-BINOL as chiral cata-
lyst gave enantiomerically pure adduct 2 with the 
S configuration of C3 [17]. The carbamate moieties 
were removed from 2 by heating in boiling dioxane 
for 3 h in the presence of 2 M sodium hydroxide, 
followed by acidification with an acidic ion exchanger 
(Amberlite®, H-form). Pure compound 3 was isolated 
in 91% yield by recrystallization from acetone 
(Scheme 1). The 2-position in 3 was protected by treat-
ment with Boc2O, and new N-Boc-1-azafagomine 4 
thus obtained (yield 93%) was reacted with triphosgene 
in the presence of DIPEA in an inert atmosphere. As 
a result, bicyclic compound 5 was formed in 5 min and 
was isolated in 90% yield after purification by column 
chromatography. Finally, deprotection of 5 by the ac-
tion of trifluoroacetic acid in methylene chloride at 
room temperature afforded target product 6.
(2E)-Penta-2,4-dien-1-ol (1) was synthesized ac-
cording to the procedure described in [16]. Yield 5 g 
(31.4%). 1H NMR spectrum (CDCl3), δ, ppm: 3.12 br.s 
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(1H, OH), 4.07 m (2H, CH2OH), 5.01 d (1H, CH, 
J = 9.6 Hz), 5.13 d (1H, CH, J = 16.4 Hz), 5.74 d.t 
(1H, CH=CH2OH, J = 14.7, 5.7 Hz), 6.25 m (2H, 
CH2=CH). 13C NMR spectrum (CDCl3), δC, ppm: 62.3 
(CH2), 116.9 (CH2), 131.2 (CH), 132.5 (CH), 136.2 
(CH). Found, %: C 71.47; H 9.48. C5H8O. Calculated, 
%: C 71.42; H 9.52.
Diethyl (3S)-3-(hydroxymethyl)pyridazine-1,2-
(3H,6H)-dicarboxylate (2). A 1.2 M solution of 
Me2Zn in toluene (991 μL, 1.19 mmol) was added at 
0°C to a solution of 0.100 g (1.19 mmol) of penta-2,4-
dien-1-ol (1) in anhydrous toluene (6 mL), and the 
mixture was stirred for 5 min. Solution A was thus 
obtained. A 1.4 M solution of MeMgBr in toluene/THF 
(849 μL, 1.19 mmol) was added at 0°C to a solution of 
0.340 g (1.19 mmol) of (S)-BINOL in 6 mL of anhy-
drous toluene, and the mixture was stirred for 5 min to 
obtain solution B. Solution A was diluted with anhy-
drous toluene (10 mL) and added to solution B, and 
the mixture was stirred for 5 min and cooled to –78°C. 
A solution of diethyl azodicarboxylate (543 μL, 
1.19 mmol) in anhydrous toluene (10 mL) was added, 
and the mixture was stirred for 5 min at –78°C, allowed 
to slowly warm up to room temperature, and stirred for 
18 h. The mixture was then quenched with a saturated 
solution of sodium hydrogen carbonate (1 mL) and 
filtered, and the precipitate was washed with ethyl 
acetate (3×20 mL). The filtrate was combined with the 
washings and evaporated under reduced pressure, and 
the residue (yellow oil) was purified by column chro-
matography using petroleum ether–diethyl ether (1:1) 
as eluent. In addition, (S)-BINOL, 0.200 g (69%), was 
partially recovered during chromatographic purifica-
tion. Yield of 2 0.225 g (73%), yellow oil, [α]D20 = 
–23.4° (c = 1.25, CHCl3). IR spectrum, ν, cm–1: 3483 
(OH), 1707 (C=O). 1H NMR spectrum (CDCl3) δ, 
ppm: 1.23–1.30 m (12H, CH3), 2.58 br.s (1H, OH), 
3.35 d.d (1H, J = 12.3, 9.5 Hz), 3.45 d.d (1H, J = 12.0, 
9.8 Hz), and 3.56–3.69 m (2H) (CH2OH); 3.77 d.d 
(1H, 6-H, J = 13.5, 4.3 Hz), 3.91 br.s (1H, 6-H), 4.11–
4.26 m (8H, OCH2), 4.30 t.d.d (1H, 6-H, J = 6.0, 3.9, 
2.2 Hz), 4.34–4.44 m (1H, 6-H), 4.72 br.s (2H, 3-H), 
5.66–5.88 m (4H, 4-H, 5-H). 13C NMR spectrum 
(CDCl3), δC, ppm: 14.30 and 14.40 (CH3CH2), 42.20 
and 43.60 (C6), 55.90 and 56.90 (C3), 61.90 (CH2OH); 
62.60, 62.70, 62.80, and 62.90 (CH2CH3); 123.40, 
124.20, 124.60, and 125.20 (C4, C5); 154.90, 155.70, 
156.20,  and 156.30 (C=O).  Mass spectrum: 
m/z 281.1108 [M + Na]+. Found, %: C 51.21; H 6.91; 
N 10.81. C11H18N2O5. Calculated, %: C 51.16; H 6.97; 
N 10.85.
(S)-(1,2,3,6-Tetrahydropyridazin-3-yl)methanol 
(3). Compound 2, 0.119 g (0.461 mmol), was dissolved 
in 2 mL of THF, 2 mL of 2 M aqueous sodium hydrox-
ide was added, and the mixture was refluxed for 3 h. 
The mixture was cooled, 2 mL of THF and a suspen-
sion of Amberlite® (H-form) in water were added, the 
mixture was stirred and filtered with suction, and the 
solvent was distilled off from the filtrate. Yield 0.048 g 
(91.0%), yellow oil, [α]D20 = –20° (c = 0.3, EtOH). IR 
spectrum, ν, cm–1: 3422 (N–H), 1643 (C=C). 1H NMR 
spectrum (D2O), δ, ppm: 3.24 d.d.d (1H, 6-H, J = 2.6, 
3.2, 17.2 Hz), 3.35 d.d.d (1H, 6-H, J = 2.8, 5.2, 
17.6 Hz), 3.48–3.54 m (1H, 3-H), 3.57–3.65 m (2H, 
CH2OH), 5.79 d.d.d (1H, 4-H, J = 2.0, 4.4, 10.4 Hz), 
6.01 d.d.d (1H, 5-H, J = 2.4, 5.6, 10.4 Hz). 13C NMR 
spectrum (D2O), δC, ppm: 44.2 (C6), 54.8 (C3), 62.5 
(CH2OH), 125.0 (C4), 127.4 (C5). Mass spectrum: 
m/z 114.0793 [M + H]+. Found, %: C 52.67; H 8.74; 
N 24.51. C5H10N2O. Calculated, %: C 52.63; H 8.77; 
N 24.56.
tert-Butyl (S)-3-(hydroxymethyl)-3,6-dihydro-
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ide, 0.015 g (0.385 mmol), and Boc2O, 0.015 g 
(0.385 mmol), were added to a mixture of 0.044 g 
(0.385 mmol) of compound 3 and 10 mL of ethanol. 
The mixture was stirred for 1 h at room temperature 
and filtered, and the precipitate was thoroughly washed 
with ethanol. The solution was concentrated to obtain 
a yellow solid which was dissolved in acetone, and the 
solution was filtered and evaporated. Yield 0.077 g 
(93%), yellow oil, [α]D20 = +67° (c = 0.78, CH2Cl2). IR 
spectrum, ν, cm–1: 3269 (OH), 1694 (CO). 1H NMR 
spectrum (D2O), δ, ppm: 1.50 s (9H, t-Bu), 3.56–
3.68 m (3H, 3-H, 3-CH2), 3.96 br.d and 4.09 br.d (1H 
each, 6-H, J = 10.0 Hz), 5.90 br.d (1H, 4-H, J = 
8.8 Hz), 5.96 br.d (1H, 5-H, J = 8.8 Hz). 13C NMR 
spectrum (D2O), δC, ppm: 27.6 [C(CH3)3], 55.9 (C3), 
61.8 (3-CH2), 82.7 [C(CH3)3], 125.0 (C5), 125.1 (C4), 
156.8 (C=O). Mass spectrum: m/z 214.1317 [M + H]+. 
Found, %: C 56.11; H 8.37; N 13.05. C10H18N2O3. 
Calculated, %: C 56.07; H 8.41; N 13.08.
tert-Butyl (4aS)-7-oxo-4a,5-dihydro-7H-oxazolo-
[3,4-b]pyridazine-1(2H)-carboxylate (5). Com-
pound 4, 0.114 g (0.532 mmol), was mixed with 10 mL 
of  anhydrous methylene chlor ide,  0 .93 mL 
(0.532 mmol) of DIPEA and 0.077 g (0.532 mmol) of 
triphosgene were added, and the mixture was stirred 
for 5 min at room temperature in a nitrogen atmo-
sphere. The solvent was distilled off, and the residue 
was purified by column chromatography using ethyl 
acetate–petro leum ether (1:1) as eluent. Yield 0.077 g 
(90%), yellow oil, [α]D20 = +30° (c = 0.4, CH2Cl2). IR 
spectrum: ν 1717 cm–1 (C=O). 1H NMR spectrum 
(DMSO-d6), δ, ppm: 3.46 d (1H, J = 11.2, 7.2 Hz), 
3.55 d.d (1H, J = 11.2, 4.8 Hz), 3.71 br.s (1H), 4.02 d.d 
(2H, J = 4.8, 2.4 Hz), 5.86 d.d.d (1H, J = 8.4, 4.8, 
2.0 Hz), 5.89 d.m (1H, J = 8.8 Hz). 13C NMR spectrum 
(DMSO-d6), δC, ppm: 27.4, 27.7, 27.8, 27.9 (CH3), 
43.3, 43.8 (CH2N), 53.0, 55.6, 56.2 (CH), 59.9, 60.4 
(CH2O), 81.6, 83.0 (C=O), 123.8–124.5 (CH), 152.6 
(C=O), 153.6 (C=O). Mass spectrum: m/z 240.0793 
[M + H]+. Found, %: C 55.05; H 6.63; N 11.69. 
C11H16N2O4. Calculated, %: C 55.00; H 6.66; N 11.66.
(S)-1,2,4a,5-Tetrahydro-7H-oxazolo[3,4-b]pyrid-
azin-7-one (6). Trifluoroacetic acid, 2.76 mL 
(0.574 mmol), was added to a solution of 0.138 g 
(0.574 mmol) of compound 5 in 11 mL of methylene 
chloride, and the mixture was stirred for 2 h at room 
temperature. The mixture was then treated with a satu-
rated solution of sodium hydrogen carbonate and 
extracted with ethyl acetate (3×30 mL). The organic 
phase was dried over MgSO4, the solvent was distilled 
off, and the residue was purified by column chromatog-
raphy using ethyl acetate–petroleum ether (2 : 1) as 
eluent. Yield 0.061 g (76%), yellow oil. IR spectrum, ν, 
cm–1: 2926 (N–H), 1788 (C=C), 1729 (C=O). 1H NMR 
spectrum (CDCl3), δ, ppm: 3.90–4.03 d.d.d (1H, J = 
18.4, 3.6, 2.0 Hz), 4.20–4.26 m (2H), 4.45–4.50 m 
(1H), 4.52–4.58 m (1H), 4.62 d.d (1H, J = 8, 1.2 Hz), 
5.87 br.d (1H, J = 8.4 Hz), 6.00–6.10 m (1H). 
13C NMR spectrum (CDCl3), δC, ppm: 39.7 (CH2N), 
47.6 (CH2N), 52.9, 53.7 (CH), 67.10, 67.12 (CH2O), 
124.3, 124.7, 125.8, 125.9 (CH), 156.4–156.6 (C=O). 
Mass spectrum: m/z 140.0586 [M + H]+. Found, %: 
C 51.42; H 5.75; N 19.99. C6H8N2O2. Calculated, %: 
C 51.48; H 5.81; N 19.91.
All commercially available reagents (Merck) were 
used without further purification. The progress of reac-
tions was monitored by TLC on Silufol UV-254 plates. 
The optical rotations were measured on an Autopol III 
polarimeter. Elemental analysis was performed with 
a Carlo Erba 1108 analyzer. The NMR spectra were 
recorded on a Bruker Avance 400 spectrometer 
(Germany) at 400 and 100.6 MHz, respectively. The IR 
spectra were recorded in the range 4000–400 cm–1 on 
a Bomem MB 104 spectrometer at room temperature. 
The high-resolution mass spectra (electrospray ioniza-
tion) were obtained on Varian 500-MS LC Ion Trap 
and VG AutoSpec-M mass spectrometers.
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